检索结果-南通市图书馆

First Trimester Pregnancy Loss May Temporary Reduce the Ovarian Response during the Subsequent IVF Cycle

Open Journal of Obstetrics and Gynecology 2018年第4期8卷 344-353页

作者： dina levitas Avi Harlev Michael Friger Iris Har-Vardi Atif Zeadna Eliahu levitas Fertility and IVF Unit Department Of Obstetrics and Gynecology Faculty of Health Sciences Soroka Medical Center Beer-Sheva Israel Department of Epidemiology Ben-Gurion University of the Negev Beer-Sheva Israel

The aim of this study was to compare the in vitro fertilization (IVF) cycles ended by miscarriage with subsequent IVF cycles in relation to various IVF cycle parameters and pregnancy termination modalities. Comparison of pre-miscarriage to post-miscarriage IVF cycles parameters demonstrated that lower peak E2 levels (1087 ± 593 versus 1237 ± 676 pg/ml, respectively;p p p p p p < 0.05), and an increase in the conception rate (34.7% versus 42.2%, respectively) at the second post-miscarriage IVF cycle.

关键词： IVF Miscarriage First Trimester Pregnancy Loss Superovulation Ovarian Response Endometrial Thickness Conception Rates

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

ROS1 in Squamous Non-Small Cell Lung Cancer—Combined Immunotherapy (PD1/CTLA4) or Targeted Therapy?

引用

Journal of Cancer Therapy 2020年第6期11卷 365-370页

作者： Alexander Yakobson Tal Mor levitas dina Laila C. Roisman Daniel Levin Wafeek Alguayn Sara Morgenstern Keren Rouvinov Nir Peled Waleed Kian The Legacy Heritage Oncology Center & Dr. Larry Norton Institute Soroka Medical Center & Ben-Gurion University Beer-Sheva Israel Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel Faculty of Health Sciences Ben-Gurion University of the Negev Beer-Sheva Israel Rabin Medical Center Beilinson Campus Petah Tikva Israel

ROS1 oncogenic fusion is reported to be 1% - 2% of non-small cell lung cancers (NSCLCs) of the adenocarcinoma subgroup. Meanwhile, there are no records of squamous cell cancer patients with tumors harboring ROS1 fusions. The Foundation Medicine database indicates a frequency of ROS1 rearrangements is 0.2% among squamous NSCLC. Crizotinib is known to be very effective in these patients. Here we present a non-smoker patient who had pure squamous NSCLC that was treated by combinational immunotherapy under a clinical trial and progressed after 2 cycles. Surprisingly, comprehensive genomic profiling detected a rare oncogenic EZR-ROS1 fusion, and the patient was treated by crizotinib with a significant response within 6 weeks. To date, the patient has been on therapy for 42 months and has achieved a complete metabolic response.

关键词： ROS1 Crizotinib Squamous Cell Lung Cancer Immunotherapy Non-Small Cell Lung Cancer

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：